Management of Stage 1 Hypertension in Adults with a Low 10-Year Risk for Cardiovascular Disease: Filling a Guidance Gap: A Scientific Statement from the American Heart Association

Daniel W. Jones, Paul K. Whelton, Norrina Allen, Donald Clark, Samuel S. Gidding, Paul Muntner, Shawna Nesbitt, Nia S. Mitchell, Raymond Townsend, Bonita Falkner

Research output: Contribution to journalArticlepeer-review

Abstract

High blood pressure (BP) is the leading cause of worldwide cardiovascular disease morbidity and mortality. Patients and clinicians dealing with hypertension have benefited from the evidence of event-based randomized controlled clinical trials. One result from those trials has been the development of evidence-based guidelines. The commitment to using evidence from these event-based randomized trials has been a cornerstone in the development of guideline treatment recommendations. However, in some situations, evidence from event-based trials is not available to guideline writers or clinicians for assistance in treatment decision making. Such is the case for the management of many patients with stage 1 hypertension. The purpose of this scientific statement is to provide information complementary to the 2017 Hypertension Clinical Practice Guidelines for the patient with untreated stage 1 hypertension (systolic BP/diastolic BP, 130-139/80-89 mm Hg) with a 10-year risk for atherosclerotic cardiovascular disease <10% who fails to meet the systolic BP/diastolic goal (<130/80 mm Hg) after 6 months of guideline-recommended lifestyle therapy. This statement provides evidence from sources other than event-based randomized controlled clinical trials and offers therapy options for consideration by clinicians.

Original languageEnglish (US)
Pages (from-to)E58-E67
JournalHypertension
DOIs
StateAccepted/In press - 2021

Keywords

  • AHA Scientific Statements
  • heart disease risk factors
  • hypertension
  • pharmacotherapy

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Management of Stage 1 Hypertension in Adults with a Low 10-Year Risk for Cardiovascular Disease: Filling a Guidance Gap: A Scientific Statement from the American Heart Association'. Together they form a unique fingerprint.

Cite this